Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRINZOLAMIDE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Open-angle glaucoma,Ocular hypertension
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
1 drop of 1% solution in the affected eye(s) twice daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily metabolized via hepatic cytochrome P450 isoenzymes, including CYP3A4, CYP2A6, CYP2C8, and CYP2C9, to its major metabolite N-desethylbrinzolamide.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~60% bound to plasma proteins (primarily albumin, also carbonic anhydrase in RBCs)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.13–0.25 L/kg (confined primarily to plasma and RBCs; low Vd due to high tissue binding)
4-6 L/kg; large Vd indicates extensive tissue distribution
Ophthalmic: systemic bioavailability ~10% (via corneal absorption); oral: not clinically used
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-60 m L/min, use with caution; no specific dose adjustment recommended but monitor for metabolic acidosis.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and efficacy not established in pediatric patients (no approved dosing).
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment required; use with caution due to increased risk of corneal edema and metabolic acidosis in elderly patients.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Sulfonamide allergy: can cause serious adverse reactions similar to systemic sulfonamides, including Stevens-Johnson syndrome and toxic epidermal necrolysis.,Corneal endothelial function: use with caution in patients with compromised corneas due to potential for edema.,Bacterial keratitis: risk from contaminated ophthalmic solutions.,Ocular effects: may cause blurred vision, eye discomfort, and other local reactions.,Systemic effects: possible metabolic acidosis, especially in patients with renal impairment or concurrent oral carbonic anhydrase inhibitors.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to brinzolamide or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min) or hyperchloremic acidosis due to risk of metabolic acidosis,Concomitant use with oral carbonic anhydrase inhibitors (additive systemic effects)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No direct food interactions. However, brinzolamide may cause metabolic acidosis, so avoid carbonic anhydrase inhibitors (e.g., acetazolamide) and limit sodium bicarbonate intake. No specific dietary restrictions.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenic effects unknown; second and third trimesters: possible fetal acidosis due to maternal carbonic anhydrase inhibition.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excretion in human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. Consider alternative therapy.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No pharmacokinetic studies in pregnancy; no dose adjustment recommended. Consider that pregnancy-induced physiologic changes (increased Vd, renal clearance) may reduce drug exposure; monitor clinical response.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Brinzolamide is a carbonic anhydrase inhibitor used topically for ocular hypertension. It reduces intraocular pressure by decreasing aqueous humor secretion. Unlike systemic CAIs, it causes fewer systemic side effects but may still cause metabolic acidosis in susceptible patients. Avoid use in patients with sulfonamide allergy due to cross-sensitivity. Monitor corneal endothelial function in patients with compromised corneas. Shake suspension well before use.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Shake the bottle well before each use.,Instill one drop in the affected eye(s) three times daily.,Wash hands before and after administration.,Remove contact lenses before instilling and wait 15 minutes before reinserting.,Do not touch the dropper tip to any surface.,Report any signs of allergy or severe eye discomfort.,May cause temporary blurred vision; avoid driving until clear.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Brinzolamide, a carbonic anhydrase inhibitor used for glaucoma, can reduce intraocular pressure and may cause systemic acidosis. Ketoconazole, an azole antifungal, inhibits CYP3A4 and can increase the systemic exposure of drugs metabolized by this enzyme. Although brinzolamide is primarily eliminated renally, co-administration may lead to additive metabolic acidosis, potentially enhancing ketoconazole's toxicity due to altered pH-dependent drug distribution and clearance."
"Olsalazine, a prodrug of mesalamine used for ulcerative colitis, can cause metabolic acidosis via carbonic anhydrase inhibition in the kidney. Brinzolamide, a topical carbonic anhydrase inhibitor for glaucoma, may additively reduce renal bicarbonate reabsorption, increasing the risk of hyperchloremic metabolic acidosis and electrolyte disturbances. Concurrent use may exacerbate acidosis, leading to symptoms like tachypnea, fatigue, and confusion."
"The combination of two carbonic anhydrase inhibitors, Brinzolamide (ophthalmic) and Diclofenamide (systemic), can lead to additive inhibition of carbonic anhydrase in renal tubules, resulting in enhanced systemic absorption and elevated plasma concentrations of Brinzolamide. This may cause severe metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and increased risk of sulfonamide-related adverse effects such as Stevens-Johnson syndrome. Patients may present with confusion, tachypnea, cardiac arrhythmias, or acute kidney injury."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRINZOLAMIDE vs ABSTRAL, answered by our medical review team.
BRINZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRINZOLAMIDE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRINZOLAMIDE is: 1 drop of 1% solution in the affected eye(s) twice daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRINZOLAMIDE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRINZOLAMIDE is classified as Category A/B. Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy . ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.